381 related articles for article (PubMed ID: 34681685)
1. IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives.
Španko M; Strnadová K; Pavlíček AJ; Szabo P; Kodet O; Valach J; Dvořánková B; Smetana K; Lacina L
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681685
[TBL] [Abstract][Full Text] [Related]
2. Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer.
Reers S; Pfannerstill AC; Rades D; Maushagen R; Andratschke M; Pries R; Wollenberg B
Anticancer Res; 2013 Jun; 33(6):2481-9. PubMed ID: 23749899
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma.
Jinno T; Kawano S; Maruse Y; Matsubara R; Goto Y; Sakamoto T; Hashiguchi Y; Kaneko N; Tanaka H; Kitamura R; Toyoshima T; Jinno A; Moriyama M; Oobu K; Kiyoshima T; Nakamura S
Oncol Rep; 2015 May; 33(5):2161-8. PubMed ID: 25761055
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers.
Wallis SP; Stafford ND; Greenman J
Head Neck; 2015 Mar; 37(3):449-59. PubMed ID: 24803283
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR
PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer.
Gallo O; Gori AM; Attanasio M; Martini F; Giusti B; Boddi M; Gallina E; Fini O; Abbate R
Br J Cancer; 1993 Sep; 68(3):465-8. PubMed ID: 8353036
[TBL] [Abstract][Full Text] [Related]
7. Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment.
Nisar S; Yousuf P; Masoodi T; Wani NA; Hashem S; Singh M; Sageena G; Mishra D; Kumar R; Haris M; Bhat AA; Macha MA
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925575
[TBL] [Abstract][Full Text] [Related]
8. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway.
Yadav A; Kumar B; Datta J; Teknos TN; Kumar P
Mol Cancer Res; 2011 Dec; 9(12):1658-67. PubMed ID: 21976712
[TBL] [Abstract][Full Text] [Related]
9. [B cells in head and neck oncology].
Schuler PJ; Brunner C; Hoffmann TK
HNO; 2018 Apr; 66(4):296-300. PubMed ID: 29500500
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
11. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas.
Rydberg C; Månsson A; Uddman R; Riesbeck K; Cardell LO
Immunology; 2009 Sep; 128(1 Suppl):e600-11. PubMed ID: 19740321
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo interleukin (IL)-1 beta, IL-6, IL-12 and tumor necrosis factor-alpha responsiveness with monocytes from patients with head and neck carcinoma.
Heimdal JH; Aarstad HJ; Klementsen B; Olofsson J
Eur Arch Otorhinolaryngol; 1999; 256(5):250-6. PubMed ID: 10392301
[TBL] [Abstract][Full Text] [Related]
14. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.
Yu CC; Tsai LL; Wang ML; Yu CH; Lo WL; Chang YC; Chiou GY; Chou MY; Chiou SH
Cancer Res; 2013 Jun; 73(11):3425-40. PubMed ID: 23548270
[TBL] [Abstract][Full Text] [Related]
15. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
Tsai MS; Chen WC; Lu CH; Chen MF
Oral Oncol; 2019 Apr; 91():47-55. PubMed ID: 30926062
[TBL] [Abstract][Full Text] [Related]
16. Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.
Evrard D; Szturz P; Tijeras-Raballand A; Astorgues-Xerri L; Abitbol C; Paradis V; Raymond E; Albert S; Barry B; Faivre S
Oral Oncol; 2019 Jan; 88():29-38. PubMed ID: 30616794
[TBL] [Abstract][Full Text] [Related]
17. Adenosine-producing regulatory B cells in head and neck cancer.
Jeske SS; Brand M; Ziebart A; Laban S; Doescher J; Greve J; Jackson EK; Hoffmann TK; Brunner C; Schuler PJ
Cancer Immunol Immunother; 2020 Jul; 69(7):1205-1216. PubMed ID: 32146518
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 signaling pathway in targeted therapy for cancer.
Guo Y; Xu F; Lu T; Duan Z; Zhang Z
Cancer Treat Rev; 2012 Nov; 38(7):904-10. PubMed ID: 22651903
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
Takahashi H; Sakakura K; Kudo T; Toyoda M; Kaira K; Oyama T; Chikamatsu K
Oncotarget; 2017 Jan; 8(5):8633-8647. PubMed ID: 28052009
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
